HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women

Molecular and Cellular Biochemistry

Volumn 357, Issue 1-2, 2011, Pages 247-253

  Batschauer, Anna P ^a   Cruz, Nathalia G ^a   Oliveira, Vanessa C ^b   Coelho, Fernanda F ^a   Santos, Izabela R ^a   Alves, Michelle T ^a   Fernandes, Ana P ^a   Carvalho, Maria G ^a   Gomes, Karina B ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hermes Pardini Institute   (Brazil)

Author keywords

Breast cancer; FGFR4; HFE; MTHFR; Prognostic markers

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; HEMOJUVELIN; PROGESTERONE RECEPTOR; PROTEIN P53; FGFR4 PROTEIN, HUMAN; HER2 PROTEIN, HUMAN; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ARTICLE; BRAZIL; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; BREAST TUMOR; CANCER STAGING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

BRAZIL; BREAST NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; MEMBRANE PROTEINS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 84857413634     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0895-1     Document Type: Article

References (23)

1. Wogan GN, Hecht SS, Felton JS et al (2004) Environmental and chemical carcinogenesis. Semin Cancer Biol 14(6):473-486 (Pubitemid 39360995)
2. Campbell IG, Baxter SW, Eccles DM et al (2002) Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4(6):R14
3. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4(6):470-480 (Pubitemid 38745532)
4. Spinola M, Leoni VP, Tanuma J et al (2005) FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 14(2):415-419
5. Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24(23):3747-3755 (Pubitemid 46622313)
6. Xu WH, Shrubsole MJ, Xiang YB et al (2007) Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 16(2):281-287 (Pubitemid 46383347)
7. Jezequel P, Campion L, Joalland MP et al (2004) G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 90(1):189-193 (Pubitemid 38174960)
8. Marmé F, Werft W, Benner A et al (2010) FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol 21(8):1636-1642
9. Naidu R, Har YC, Taib NA (2009) Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res 18(2-3):65-71
10. Ericson U, Sonestedt E, Ivarsson M et al (2009) Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmö Diet and Cancer cohort. Cancer Epidemiol Biomarkers Prev 18(4):1101-1110
11. Gao CM, Tang JH, Cao HX et al (2009) MTHFR polymorphisms, dietary folate intake and breast cancer risk in Chinese women. J Hum Genet 54(7):414-418
12. Chou YC, Wu MH, Yu JC et al (2006) Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis 27(11):2295-2300
13. Xu X, Gammon M, Zhang H et al (2007) Polymorphisms of one-carbon-metabolizing genes and risk of breast cancer in a population-based study. Carcinogenesis 28(7):1504-1509 (Pubitemid 47241800)
14. Mohammad NS, Yedluri R, Addepalli P et al (2011) Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol Cell Biochem 349:159-167
15. Kondrashova TV, Neriishi K, Ban S et al (2006) Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta 1762(1):59-65 (Pubitemid 43021087)
16. Green R, Esparza I, Schreiber R (1988) Iron inhibits the nonspecific tumoricidal activity of macrophages: a possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci 526:301-309
17. Bergeron R, Streiff RR, Elliott GT (1985) Influence of iron on in vivo proliferation and lethality of L1210 cells. J Nutr 115(3): 369-374 (Pubitemid 15138801)
18. Gunel-ozcan A, Alyilmaz-Bekmez S, Guler E, Guc D (2006) HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer 6:37
19. Kallianpur AR, Hall LD, Yadav M et al (2004) Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 13(2):205-212 (Pubitemid 38222550)
20. Abraham B, Justenhoven C, Pesch B et al (2005) Network investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev 14:1102-1107 (Pubitemid 40656454)
21. Ariga R, Zarif A, Korasick J et al (2005) Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11:278-280 (Pubitemid 41026044)
22. Lang J, Mosalpuria K, Cristofanilli M et al (2009) HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res 113:501-507
23. Xu W, Li Y, Wang X et al (2010) FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Eur J Cancer 46(18):3332-3338